ASCO 2024 Highlights

Biomarker testing is crucial in guiding treatment choices by pinpointing individuals who stand to gain from specific regimens, ultimately enhancing patient results. Nevertheless, the application of guideline-endorsed biomarker testing for advanced non–small cell lung cancer patients varies. Read More ›

MCLA-129 is a Biclonics-based product that can be categorized as a common light chain/bispecific antibody used to target EGFR and c-MET while enhancing antibody-dependent cellular cytotoxicity. Read More ›

Prostate cancer ranks as the second most common cause of cancer-related deaths among men in the United States. Aggressive forms of this cancer are linked to mutations in homologous recombination repair genes. Read More ›

Despite recommendations, genetic testing for advanced prostate cancer is not widely used and may not be readily accepted by patients. This analysis investigated the attitudes and decisional conflicts surrounding genetic testing and the differences between White and non-White patients. Read More ›

Disparities have been extensively documented in prostate cancer screening uptake and shared decision-making conversations among racial and sexual minorities. Yet, the impact of racial/ethnic identity and sexual orientation on prostate-specific antigen testing uptake remains uncertain. Read More ›

Messenger ribonucleic acid (mRNA)-4157 is an innovative approach to personalized neoantigen therapy. It utilizes mRNA to enhance the body’s natural immune response against tumor cells by targeting specific mutations unique to each patient. Read More ›

Updates from ASCO on the latest research and treatment advancements in cancer. Read More ›